NS 018

Drug Profile

NS 018

Alternative Names: NS-018

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Nippon Shinyaku
  • Class Antineoplastics
  • Mechanism of Action Janus kinase-2 inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myelofibrosis
  • Discontinued Haematological disorders

Most Recent Events

  • 03 Dec 2016 Phase-II clinical trials in Myelofibrosis in USA (PO)
  • 03 Dec 2016 Efficacy and adverse events data from a phase I/II trial Myelofibrosis presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 03 Dec 2016 Nippon Shinyaku completes enrollment in its phase I/II trial in Myelofibrosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top